WO1999012964A2 - Kay, nouvelle proteine du systeme immunitaire - Google Patents

Kay, nouvelle proteine du systeme immunitaire Download PDF

Info

Publication number
WO1999012964A2
WO1999012964A2 PCT/US1998/019037 US9819037W WO9912964A2 WO 1999012964 A2 WO1999012964 A2 WO 1999012964A2 US 9819037 W US9819037 W US 9819037W WO 9912964 A2 WO9912964 A2 WO 9912964A2
Authority
WO
WIPO (PCT)
Prior art keywords
ligand
kay
seq
cell
receptor
Prior art date
Application number
PCT/US1998/019037
Other languages
English (en)
Other versions
WO1999012964A3 (fr
Inventor
Jurg Tschopp
Original Assignee
Biogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP98946052A priority Critical patent/EP1012270A2/fr
Priority to JP2000510769A priority patent/JP2001515711A/ja
Priority to HU0004034A priority patent/HUP0004034A3/hu
Priority to SK353-2000A priority patent/SK3532000A3/sk
Application filed by Biogen, Inc. filed Critical Biogen, Inc.
Priority to AU93152/98A priority patent/AU9315298A/en
Priority to CA002303424A priority patent/CA2303424A1/fr
Priority to EA200000311A priority patent/EA200000311A1/ru
Priority to IL13448098A priority patent/IL134480A0/xx
Priority to BR9812433-1A priority patent/BR9812433A/pt
Priority to EEP200000148A priority patent/EE200000148A/xx
Priority to KR1020007002576A priority patent/KR20010023892A/ko
Publication of WO1999012964A2 publication Critical patent/WO1999012964A2/fr
Publication of WO1999012964A3 publication Critical patent/WO1999012964A3/fr
Priority to IS5375A priority patent/IS5375A/is
Priority to NO20001240A priority patent/NO20001240L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to a novel ligand, Kay, which is a member of the Tumor Necrosis Factor Family.
  • This protein or its receptor may have anti-cancer and/or immunoregulatory applications.
  • cells transfected with the genes for this novel ligand may be used in gene therapy to treat tumors, autoimmune and inflammatory diseases or inherited genetic disorders, and blocking antibodies to these proteins can have immunoregulatory applications.
  • TNF tumor-necrosis factor
  • the tumor-necrosis factor (TNF)-related cytokines are mediators of host defense and immune regulation.
  • Members of this family exist in membrane-anchored forms, acting locally through cell-to-cell contact, or as secreted proteins capable of diffusing to more distant targets.
  • TNF family of ligands and receptors has at least 11 recognized receptor-ligand pairs, including: TNF:TNF-R; LT- ⁇ .TNF-R; LT- ⁇ / ⁇ .LT- ⁇ -R; FasL.Fas; CD40L.CD40; CD30L.CD30; CD27L.CD27; OX40L.OX40 and 4-1BBL.4-1BB.
  • the DNA sequences encoding these ligands have only about 25% to about 30% identity in even the most related cases, although the amino acid relatedness is about 50%.
  • This family of genes encodes glycoproteins characteristic of Type I transmembrane proteins with an extracellular ligand binding domain, a single membrane spanning region and a cytoplasmic region involved in activating cellular functions.
  • the cysteine-rich ligand binding region exhibits a tightly knit disulfide linked core domain, which, depending upon the particular family member, is repeated multiple times.
  • Most receptors have four domains, although there may be as few as three, or as many as six.
  • Proteins in the TNF family of ligands are characterized by a short N-terminal stretch of normally short hydrophilic amino acids, often containing several lysine or arginine residues thought to serve as stop transfer sequences. Next follows a transmembrane region and an extracellular region of variable length, that separates the
  • the C-terminal binding region comprises the bulk of the protein, and often, but not always, contains glycosylation sites. These genes lack the classic signal sequences characteristic of type I membrane proteins, type II membrane proteins with the C terminus lying outside the cell, and a short N-terminal domain residing in the cytoplasm. In some cases, e.g., TNF and LT- ⁇ , cleavage in the stalk region can occur early during protein processing and the ligand is then found primarily in secreted form. Most ligands, however, exist in a membrane form, mediating localized signaling.
  • TNF and lymphotoxin- ⁇ are both structured into a sandwich of two anti-parallel ⁇ -pleated sheets with the "jelly roll” or Greek key topology.”
  • the rms deviation between the C ⁇ and ⁇ residues is 0.61 C, suggesting a high degree of similarity in their molecular topography.
  • a structural feature emerging from molecular studies of CD40L, TNF and LT- ⁇ is the propensity to assemble into oligomeric complexes. Intrinsic to the oligomeric structure is the formation of the receptor binding site at the junction between the neighboring subunits creating a multivalent ligand.
  • TNF, CD40L and LT- ⁇ have been shown to exist as trimers by analysis of their crystal structures. Many of the amino acids conserved between the different ligands are in stretches of the scaffold ⁇ - sheet. It is likely that the basic sandwich structure is preserved in all of these molecules, since portions of these scaffold sequences are conserved across the various family members. The quaternary structure may also be maintained since the subunit conformation is likely to remain similar.
  • TNF family members can best be described as master switches in the immune system controlling both cell survival and differentiation.
  • TNF and LT ⁇ are currently recognized as secreted cytokines contrasting with the other predominantly membrane anchored members of the TNF family.
  • a membrane form of TNF has been well-characterized and is likely to have unique biological roles, secreted TNF functions as a general alarm signaling to cells more distant from the site of the triggering event.
  • TNF secretion can amplify an event leading to the well-described changes in the vasculature lining and the inflammatory state of cells.
  • the membrane bound members of the family send signals though the TNF type receptors only to cells in direct contact.
  • T cells provide CD40 mediated
  • TNF TNF
  • Fas ligand and TRAIL can efficiently induce cell death in many lines and their receptors mostly likely have good canonical death domains. Presumably the ligand to DR-3 (TRAMP/WSL-1) would also all into this category.
  • TWEAK TWEAK
  • CD30 ligand and LTalb2 TWEAK
  • LTalb2 TWEAK
  • How this group can trigger cell death in the absence of a canonical death domain is an interesting question and suggests that a separate weaker death signaling mechanism exists.
  • members that cannot efficiently deliver a death signal Probably all groups can have antiproliferative effects on some cell types consequent to inducing cell differentiation e.g. CD40 (Funakoshi et al., 1994)
  • TNF family has grown dramatically in recent years to encompass at least 11 different signaling pathways involving regulation of the immune system.
  • the widespread expression patterns of TWEAK and TRAIL indicate that there is still more functional variety to be uncovered in this family.
  • This aspect has been especially highlighted recently in the discovery of two receptors that affect the ability of rous sacroma and herpes simplex virus to replicate as well as the historical observations that TNF has anti-viral activity and pox viruses encode for decoy TNF receptors (Brojatsch et al., 1996; Montgomery et al., 1996; Smith, 1994; Vassalli, 1992).
  • TNF is a mediator of septic shock and cachexia" 1 , and is involved in the regulation of hematopoietic cell development. ⁇ It appears to play a major role as a mediator of inflammation and defense against bacterial, viral and parasitic infections v as well as having antitumor activity/ 1 TNF is also involved in different autoimmune diseases/ 11 TNF may be produced by several types of cells, including macrophages, fibroblasts, T cells and natural killer cells/ 111 TNF binds to two different receptors, each acting through specific intracellular signaling molecules, thus resulting in different effects of TNF. 1X TNF can exist either as a membrane bound form or as a soluble secreted cytokine.
  • LT- ⁇ shares many activities with TNF, i.e. binding to the TNF receptors 1 but unlike TNF, appears to be secreted primarily by activated T cells and some ⁇ - lymphoblastoid tumors/ 11
  • the heteromeric complex of LT- ⁇ and LT- ⁇ is a membrane bound complex which binds to the LT- ⁇ receptor/ 111
  • the LT system (LTs and LT-R) appears to be involved in the development of peripheral lymphoid organs since genetic disruption of LT- ⁇ leads to disorganization of T and B cells in the spleen and an absence of lymph nodes/ lv
  • the LT- ⁇ system is also involved in cell death of some adenocarcinoma cell lines/ v
  • Fas-L another member of the TNF family, is expressed predominantly on activated T cells/ vl It induces the death of cells bearing its receptor, including tumor cells and HlV-infected cells, by a mechanism known as programmed cell death or apoptosis/ v " Furthermore, deficiencies in either Fas or Fas-L may lead to lymphoproliferative disorders, confirming the role of the Fas system in the regulation of immune responses/ vm The Fas system is also involved in liver damage resulting from hepatitis chronic infection xlx and in autoimmunity in HIV-infected patients/" The Fas system is also involved in T-cell destruction in HIV patients/" 1 TRAIL, another member of this family, also seems to be involved in the death of a wide variety of transformed cell lines of diverse origin/" 11
  • CD40-L another member of the TNF family, is expressed on T cells and induces the regulation of CD40-bearing B cells/" 111 Furthermore, alterations in the CD40-L gene result in a disease known as X-linked hyper-IgM syndrome/ xlv
  • the CD40 system is also involved in different autoimmune diseases xxv and CD40-L is known to have antiviral properties /" V1
  • the CD40 system is involved in the rescue of apoptotic B cells/" V11 in non-immune cells it induces apoptosis xxvm .
  • Many additional lymphocyte members of the TNF family are also involved in costimulation/" 1 "
  • the members of the TNF family have fundamental regulatory roles in controlling the immune system and activating acute host defense systems. Given the current progress in manipulating members of the TNF family for therapeutic benefit, it is likely that members of this family may provide unique means to control disease.
  • Some of the ligands of this family can directly induce the apoptotic death of many transformed cells e.g. LT, TNF, Fas ligand and TRAIL (Nagata, 1997). Fas and possibly TNF and CD30 receptor activation can induce cell death in nontransformed lymphocytes which may play an immunoregulatory function (Amakawa et al., 1996;
  • the death domain orchestrates the assembly of various signal transduction components which result in the activation of the caspase cascade (Nagata,
  • Some receptors lack canonical death domains, e.g. LTb receptor and CD30
  • the present invention is directed to a novel polypeptide referred to as Kay-ligand, which substantially obviates one or more of the problems due to the limitations and disadvantages of the related art.
  • the inventors have discovered new members of the TNF family of cytokines, and defined both the human amino acid sequence of the protein, as well as the DNA sequences encoding these proteins.
  • the claimed invention may be used to identify new diagnostics and therapeutics for numerous diseases and conditions as discussed in more detail below, as well as to obtain information about, and manipulate, the immune system and its processes. Additionally, the invention may be involved in the induction of cell death in carcinomas.
  • DNA sequences encoding Kay-ligand Specifically, the invention relates to DNA sequences which encode the human Kay-ligand , SEQ. ID. NO.: 1. Additionally, the claimed invention relates to the amino acid sequence of this novel ligand.
  • the amino acid sequence of human Kay-ligand is set forth in SEQ. ID. NO.: 2. Applicants have additionally provided in part the DNA sequence for murine Kay-ligand, SEQ. ID. NO.:
  • the invention relates to sequences that have at least 50% homology with DNA sequences encoding the C terminal receptor binding domain of the ligand and hybridize to the claimed DNA sequences or fragments thereof, and which encode the Kay- ligand having the sequences identified in SEQ. ID. NO. 1 or SEQ. ID. NO. 4.
  • the invention in certain embodiments furthermore relates to DNA sequences encoding Kay-ligand where the sequences are operatively linked to an expression control sequence.
  • Any suitable expression control sequences are useful in the claimed invention, and can easily be selected by one skilled in the art.
  • the invention also contemplates recombinant DNAs comprising a sequence encoding Kay-ligand or fragments thereof, as well as hosts with stably integrated Kay- ligand sequences introduced into their genome, or possessing episomal elements. Any suitable host may be used in the invention, and can easily be selected by one skilled in the art without undue experimentation.
  • the invention relates to methods of producing substantially pure Kay-ligands comprising the step of culturing transformed hosts. In yet other embodiments, the invention relates to the Kay ligand essentially free of normally associated animal proteins.
  • the invention encompasses Kay-ligand having the amino acid sequence identified in SEQ. ID. NO. 2. as well as fragments or homologs thereof.
  • the amino acid and/or the DNA sequences may comprise conservative insertions, deletions and substitutions, as further defined below or may comprise fragments of said sequences.
  • the invention relates in other embodiments to soluble constructs comprising Kay-ligand which may be used to directly trigger Kay-ligand mediated pharmacological events. Such events may have useful therapeutic benefits in the treatment of cancer, tumors or the manipulation of the immune system to treat immunologic diseases. Soluble forms of the claimed ligands could be genetically reengineered to incorporate an easily recognizable tag, thereby facilitating the identification of the receptors for these ligands. Additionally, in other embodiments the claimed invention relates to antibodies directed against the Kay-ligand, which can be used, for example, for the treatment of cancers, and manipulation of the immune system to treat immunologic disease.
  • the invention relates to methods of gene therapy using the genes for Kay-ligand, as disclosed and claimed herein.
  • the pharmaceutical preparations of the invention may, optionally, include pharmaceutically acceptable carriers, adjuvants, fillers, or other pharmaceutical compositions, and may be administered in any of the numerous forms or routes known in the art.
  • Figure 1 An alignment of the amino acid sequences of murine and human Kay Ligand.
  • the murine sequence in the upper line was obtained by direct cloning of the cDNA.
  • the human sequence reflects a composite of a partial cDNA sequence and 5' RACE determination.
  • the third, bottom sequence lines shows the consensus sequence.
  • FIG. 2 A fragment of human KayL cDNA was used to probe a northern blot of RNA's from various human tissues. It can be seen that a roughly 2.4 kb KayL RNA is expressed primarily in the spleen and peripheral blood lymphocytes, i.e. in the secondary lymphoid organs.
  • the invention relates to uses of these DNA sequences and the peptides encoded by them. Additionally, the invention encompasses both human and mouse amino acid sequences for Kay-ligand or fragments thereof, as well as pharmaceutical compositions comprising or derived from them.
  • homologous refers to the sequence similarity between sequences of molecules being compared. When a position in both of the two compared sequences is occupied by the same base or amino acid monomer subunit, e.g., if a position in each of two DNA molecules is occupied by adenine, then the molecules are homologous at that position.
  • the percent of homology between two sequences is a function of the number of matching or homologous positions shared by the two sequences divided by the number of positions compared x 100. For example, if 6 of 10 of the positions in two sequences are matched or homologous then the two sequences are 60% homologous.
  • the DNA sequences ATTGCC and TATGGC share 50% homology.
  • a “purified preparation” or a “substantially pure preparation” of a polypeptide means a polypeptide that has been separated from other proteins, lipids, and nucleic acids with which it naturally occurs. Preferably, the polypeptide is also separated from other substances, e.g., antibodies, matrices, etc., which are used to purify it.
  • Transformed host as used herein is meant to encompass any host with stably integrated sequence, i.e. Kay-ligand sequence, introduced into its genome or a host possessing sequence, i.e. Ligand encoding episomal elements.
  • a “treatment”, as used herein, includes any therapeutic treatment, e.g., the administration of a therapeutic agent or substance, e.g., a drug.
  • a “substantially pure nucleic acid”, e.g., a substantially pure DNA is a nucleic acid which is one or both of: (1) not immediately contiguous with either one or both of the sequences, e.g., coding sequences, with which it is immediately contiguous (i.e., one at the 5' end and one at the 3' end) in the naturally-occurring genome of the organism from which the nucleic acid is derived; or (2) which is substantially free of a nucleic acid sequence with which it occurs in the organism from which the nucleic acid is derived.
  • the term includes, for example, a recombinant DNA which is incorporated into a vector, e.g., into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (e.g., a cDNA or a genomic DNA fragment produced by PCR or restriction endonuclease treatment) independent of other DNA sequences.
  • Substantially pure DNA also includes a recombinant DNA which is part of a hybrid gene encoding Kay- ligand.
  • the terms "peptides", “proteins”, and “polypeptides” are used interchangeably herein.
  • Biologically active as used herein, means having an in vivo or in vitro activity which may be performed directly or indirectly.
  • Biologically active fragments of Kay ligand may have, for example, 70% amino acid homology with the active site of the Ligands, more preferably at least 80%, and most preferably, at least 90% homology.
  • Identity or homology with respect to the Ligands is defined herein as the percentage of amino acid residues in the candidate sequence which are identical to the Kay-ligand residues in SEQ. ID. NO. 2.
  • nucleic acid as described herein, features a substantially pure (or recombinant) nucleic acid which includes a nucleotide sequence encoding a Kay-ligand, such as the DNA described in SEQ. ED. NO. 1 and/or equivalents of such nucleic acids.
  • nucleic acid as used herein can include fragments and equivalents, such as, for example, sequences encoding functionally equivalent peptides.
  • Equivalent nucleotide sequences may include sequences that differ by one or more nucleotide substitutions, additions or deletions, such as allelic variants, mutations, etc. and include sequences that differ from the nucleotide sequence encoding Kay-ligand shown in SEQ. ID NO: 1, due to the degeneracy of the genetic code.
  • the inventor describes herein the human and sequences; the invention will be described generally by reference to the human sequences, although one skilled in the art will understand that the mouse sequences are encompassed herein.
  • the human proteins appear to have all of the characteristics of the TNF family, i.e., a type LI membrane protein organization and conservation of the sequence motifs involved in the folding of the protein into the TNF anti-parallel ⁇ -sheet structure.
  • the nucleotide sequence for Kay-ligand is set forth in SEQ. ID. NO. 1 ; the amino acid sequence for Kay-ligand is described in SEQ. ID. NO. 2.
  • the sequences of the invention can be used to prepare a series of DNA probes that are useful in screening various collections of natural and synthetic DNAs for the presence of DNA sequences that are closely related to Kay-ligand, or fragments or derivatives thereof.
  • Kay-ligand refers also to biologically active derivatives, fragments or homologs thereof.
  • the DNA sequences encoding the Kay-Ligand of the invention can be employed to produce the claimed peptides on expression in various prokaryotic and eukaryotic hosts transformed with them. These peptides may be used in anti-cancer, and immunoregulatory applications. In general, this comprises the steps of culturing a host transformed with a DNA molecule containing the sequence encoding Kay-ligand, operatively-linked to an expression control sequence.
  • DNA sequences and recombinant DNA molecules of the present invention can be expressed using a wide variety of host/vector combinations.
  • useful vectors may consist of segments of chromosomal, non-chromosomal or synthetic DNA sequences.
  • the expression vectors of the invention are characterized by at least one expression control sequence that may be operatively linked to the Kay-Ligand DNA sequence inserted in the vector, in order to control and to regulate the expression of the
  • each expression vector various sites may be selected for insertion of the Kay-Ligand sequence of the invention.
  • the sites are usually designated by a restriction endonuclease which cuts them, and these sites and endonucleases are well recognized by those skilled in the art.
  • an expression vector useful in this invention need not have a restriction endonuclease site for insertion of the desired DNA fragment. Instead, the vector may be cloned to the fragment by alternate means.
  • the expression vector, and in particular the site chosen therein for insertion of a selected DNA fragment, and its operative linking therein to an expression control sequence is determined by a variety of factors.
  • these factors include, but are not limited to, the size of the protein to be expressed, the susceptibility of the desired protein to proteolytic degradation by host cell enzymes, number of sites susceptible to a particular restriction enzyme, contamination or binding of the protein to be expressed by host cell proteins which may prove difficult to remove during purification. Additional factors which may be considered include expression characteristics such as the location of start and stop codons relative to the vector sequences, and other factors which will be recognized by those skilled in the art. The choice of a vector and insertion site for the claimed DNA sequences is determined by a balancing of these factors, not all selections being equally effective for a desired application. However, it is routine for one skilled in the art to analyze these parameters and choose an appropriate system depending on the particular application.
  • host/expression vector combinations function with equal efficiency in expressing the DNA sequences of this invention.
  • a particular selection of a host/expression vector combination may be made by those of skill in the art. Factors one may consider include, for example, the compatibility of the host and vector, toxicity to the host of the proteins encoded by the DNA sequence, ease of recovery of the desired protein, expression characteristics of the DNA sequences and expression control sequences operatively linked to them, biosafety, costs and the folding, form or other necessary post-expression modifications of the desired protein.
  • the Kay-ligand and homologs thereof produced by hosts transformed with the sequences of the invention, as well as native Kay-ligand purified by the processes of this invention, or produced from the claimed amino acid sequences, are useful in a variety of compositions and methods for anticancer, antitumor and immunoregulatory applications. They are also useful in therapy and methods directed to other diseases.
  • This invention also relates to the use of the DNA sequences disclosed herein to express this ligand under abnormal conditions, i.e. in a gene therapy setting.
  • Kay- ligand may be expressed in tumor cells under the direction of promoters appropriate for such applications. Such expression could enhance anti-tumor immune responses or directly affect the survival of the tumor.
  • the claimed ligand can also affect the survival of an organ graft by altering the local immune response. In this case, the graft itself or the surrounding cells would be modified with an engineered gene encoding Kay-ligand.
  • antisense therapy refers to administration or in situ generation of oligonucleotides or their derivatives which specifically hybridize under cellular conditions with the cellular mRNA and/or DNA encoding the ligand of interest, so as to inhibit expression of the encoded protein, i.e. by inhibiting transcription and/or translation.
  • the binding may be by conventional base pair complementarity, or, for example, in the case of binding to DNA duplexes, through specific interactions in the major groove of the double helix. In general,
  • antisense therapy refers to a range of techniques generally employed in the art, and includes any therapy which relies on specific binding to oligonucleotide sequences.
  • an antisense construct of the present invention can be delivered, for example, as an expression plasmid, which, when transcribed in the cell, produces RNA which is complementary to at least a portion of the cellular mRNA which encodes Kay-ligand.
  • the antisense construct can be an oligonucleotide probe which is generated ex vivo.
  • Such oligonucleotide probes are preferably modified oligonucleotides which are resistant to endogenous nucleases, and are therefor stable in vivo.
  • Exemplary nucleic acids molecules for use as antisense oligonucleotides are phosphoramidates, phosphothioate and methylphosphonate analogs of DNA (See, e.g.,
  • the Kay-ligand of the invention is a member of the TNF family.
  • the protein, fragments or homologs thereof may have wide therapeutic and diagnostic applications.
  • the Kay-ligand is present primarily in the spleen and in peripheral blood lymphocytes, strongly indicating a regulatory role in the immune system. Comparison of the claimed Kay-ligand sequences with other members of the human TNF family reveals considerable structural similarity. All the proteins share several regions of sequence conservation in the extracellular domain.
  • the precise three-dimensional structure of the claimed ligand is not known, it is predicted that, as a member of the TNF family, it may share certain structural characteristics with other members of the family.
  • novel polypeptides of the invention specifically interact with a receptor, which has not yet been identified.
  • the peptides and methods disclosed herein enable the identification of receptors which specifically interact with the claimed Kay- ligand or fragments thereof.
  • the claimed invention in certain embodiments includes peptides derived from
  • Kay-ligand which have the ability to bind to their receptors. Fragments of the Kay- ligands can be produced in several ways, e.g., recombinantly, by PCR, proteolytic digestion or by chemical synthesis. Internal or terminal fragments of a polypeptide can be generated by removing one or more nucleotides from one end or both ends of a nucleic acid which encodes the polypeptide. Expression of the mutagenized DNA produces polypeptide fragments. Polypeptide fragments can also be chemically synthesized using techniques known in the art such as conventional Merrifield solid phase f- moc or t-boc chemistry.
  • peptides and DNA sequences of the present invention may be arbitrarily divided into fragments of desired length with no overlap of the fragment, or divided into overlapping fragments of a desired length. Methods such as these are described in more detail below.
  • Soluble forms of the Kay-ligand can often signal effectively and hence can be administered as a drug which now mimics the natural membrane form. It is possible that the Kay-ligand claimed herein are naturally secreted as soluble cytokines, however, if not, one can reengineer the gene to force secretion. To create a soluble secreted form of Kay-ligand, one would remove at the DNA level the N-terminus transmembrane regions, and some portion of the stalk region, and replace them with a type I leader or alternatively a type LI leader sequence that will allow efficient proteolytic cleavage in the chosen expression system.
  • a skilled artisan could vary the amount of the stalk region retained in the secretion expression construct to optimize both receptor binding properties and secretion efficiency.
  • the constructs containing all possible stalk lengths i.e. N-terminal truncations, could be prepared such that proteins starting at amino acids 81 to 139 would result. The optimal length stalk sequence would result from this type of analysis.
  • the invention also includes antibodies specifically reactive with the claimed Kay-ligand or its receptors.
  • Anti-protein/anti-peptide antisera or monoclonal antibodies can be made by standard protocols (See, for example, Antibodies: A Laboratory Manual ed. by Harlow and Lane (Cold Spring Harbor Press: 1988)).
  • a mammal such as a mouse, a hamster or rabbit can be immunized with an immunogenic form of the peptide.
  • Techniques for conferring immunogenicity on a protein or peptide include conjugation to carriers, or other techniques, well known in the art.
  • An immunogenic portion of the claimed Kay-ligand or its receptors can be administered in the presence of an adjuvant.
  • the progress of immunization can be monitored by detection of antibody titers in plasma or serum.
  • Standard ELISA or other immunoassays can be used with the immunogen as antigen to assess the levels of antibodies.
  • the subject antibodies are immunospecific for antigenic determinants of Kay-ligand or its receptors, e.g. antigenic determinants of a polypeptide of SEQ. ID. NO.: 2, or a closely related human or non-human mammalian homolog (e.g. 70, 80 or 90 percent homologous, more preferably at least 95 percent homologous).
  • antigenic determinants of Kay-ligand or its receptors e.g. antigenic determinants of a polypeptide of SEQ. ID. NO.: 2, or a closely related human or non-human mammalian homolog (e.g. 70, 80 or 90 percent homologous, more preferably at least 95 percent homologous).
  • the anti-ligand or its receptors e.g. antigenic determinants of a polypeptide of SEQ. ID. NO.: 2
  • a closely related human or non-human mammalian homolog e.g. 70, 80 or 90 percent homologous, more preferably at least 95 percent homologous.
  • Kay-ligand or anti-Kay-ligand-receptor antibodies do not substantially cross react (i.e. react specifically) with a protein which is e.g., less than 80 percent homologous to SEQ. ED. NO. 2 or 6; preferably less than 90 percent homologous with SEQ. ID. NO.: 2; and, most preferably less than 95 percent homologous with SEQ. ID. NO.:2.
  • a protein which is e.g., less than 80 percent homologous to SEQ. ED. NO. 2 or 6; preferably less than 90 percent homologous with SEQ. ID. NO.: 2; and, most preferably less than 95 percent homologous with SEQ. ID. NO.:2.
  • not substantially cross react it is meant that the antibody has a binding affinity for a non- homologous protein which is less than 10 percent, more preferably less than 5 percent, and even more preferably less than 1 percent, of the binding affinity for a protein of SEQ. ED. NO. 2.
  • antibody as used herein is intended to include fragments thereof which are also specifically reactive with Kay-ligand, or its receptors.
  • Antibodies can be fragmented using conventional techniques and the fragments screened for utility in the same manner as described above for whole antibodies. For example, F(ab 2 fragments can be generated by treating antibody with pepsin. The resulting F(ab') 2 fragment can be treated to reduce disulfide bridges to produce Fab' fragments.
  • the antibodies of the present invention are further intended to include biospecific and chimeric molecules having anti-Kay-ligand or anti-Kay-ligand -receptor activity.
  • both monoclonal and polyclonal antibodies directed against Kay-ligand, Tumor-ligand and their receptors, and antibody fragments such as Fab' and F(ab') 2 , can be used to block the action of the Ligand and their respective receptor.
  • chimeric antibodies can be constructed in which the antigen binding domain from an animal antibody is linked to a human constant domain (e.g. Cabilly et al., U.S. 4,816,567, incorporated herein by reference). Chimeric antibodies may reduce the observed immunogenic responses elicited by animal antibodies when used in human clinical treatments.
  • recombinant "humanized antibodies” which recognize Kay-ligand or its receptors can be synthesized. Humanized antibodies are chimeras comprising mostly human IgG sequences into which the regions responsible for specific antigen- binding have been inserted.
  • Animals are immunized with the desired antigen, the corresponding antibodies are isolated, and the portion of the variable region sequences responsible for specific antigen binding are removed.
  • the animal-derived antigen binding regions are then cloned into the appropriate position of human antibody genes in which the antigen binding regions have been deleted.
  • Humanized antibodies minimize the use of heterologous (i.e. inter species) sequences in human antibodies, and thus are less likely to elicit immune responses in the treated subject.
  • ком ⁇ онентs can also be accomplished by making chimeric or humanized antibodies comprising variable domains and human constant domains (CHI, CH2, CH3) isolated from different classes of immunoglobulins.
  • CHI variable domains
  • CH2, CH3 human constant domains
  • antibodies with increased antigen binding site valencies can be recombinantly produced by cloning the antigen binding site into vectors carrying the human : chain constant regions.
  • standard recombinant DNA techniques can be used to alter the binding affinities of recombinant antibodies with their antigens by altering amino acid residues in the vicinity of the antigen binding sites.
  • the antigen binding affinity of a humanized antibody can be increased by mutagenesis based on molecular modeling. (Queen et al., Proc. Natl. Acad. Sci. 86: 10029-33 (1989) incorporated herein by reference.
  • Analogs of the claimed Kay-ligand can differ from the naturally occurring Kay- ligand in amino acid sequence, or in ways that do not involve sequence, or both.
  • Non- sequence modifications include in vivo or in vitro chemical derivatization of the Kay- ligand.
  • Non-sequence modifications include, but are not limited to, changes in acetylation, methylation, phosphorylation, carboxylation or glycosylation.
  • Preferred analogs include Kay-ligand biologically active fragments thereof, whose sequences differ from the sequence given in SEQ. ID NO.
  • Conservative substitutions typically include the substitution of one amino acid for another with similar characteristics, e.g. substitutions within the following groups: valine, glycine; glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and, phenylalanine, tyrosine.
  • Useful methods for mutagenesis include PCR mutagenesis and saturation mutagenesis as discussed in more detail below.
  • a library of random amino acid sequence variants can also be generated by the synthesis of a set of degenerate oligonucleotide sequences.
  • the DNA region to be mutagenized can be amplified using the polymerase chain reaction (PCR) under conditions that reduce the fidelity of DNA synthesis by Taq DNA polymerase, e.g., by using a dGTP/dATP ratio of five and adding Mn "+ to the PCR reaction.
  • PCR polymerase chain reaction
  • the pool of amplified DNA fragments can be inserted into appropriate cloning vectors to provide random mutant libraries.
  • Saturation mutagenesis allows for the rapid introduction of a large number of single base substitutions into cloned DNA fragments (Mayers et al., 1985, Science 229:242).
  • This technique includes generation of mutations, e.g., by chemical treatment or irradiation of single-stranded DNA in vitro, and synthesis of a complimentary DNA strand.
  • the mutation frequency can be modulated by modulating the severity of the treatment, and essentially all possible base substitutions can be obtained. Because this procedure does not involve a genetic selection for mutant fragments both neutral substitutions, as well as of a protein can be prepared by random mutagenesis of DNA which those that alter function, can be obtained.
  • the distribution of point mutations is not biased toward conserved sequence elements.
  • a library of homologs can also be generated from a set of degenerate oligonucleotide sequences. Chemical synthesis of degenerate sequences can be carried out in an automatic DNA synthesizer, and the synthetic genes then ligated into an appropriate expression vector. The synthesis of degenerate oligonucleotides is known in the art xxx Such techniques have been employed in the directed evolution of other proteins"TM.
  • Non-random or directed, mutagenesis techniques can be used to provide specific sequences or mutations in specific regions. These techniques can be used to create variants which include, e.g., deletions, insertions, or substitutions, of residues of the known amino acid sequence of a protein.
  • the sites for mutation can be modified individually or in series, e.g., by (1) substituting first with conserved amino acids and then with more radical choices depending upon results achieved, (2) deleting the target residue, or (3) inserting residues of the same or a different class adjacent to the located site, or combinations of options 1-3.
  • Alanine scanning mutagenesis is a useful method for identification of certain residues or regions of the desired protein that are preferred locations or domains for mutagenesis, Cunningham and Wells (Science 244: 1081-1085, 1989) specifically incorporated by reference.
  • a residue or group of target residues are identified (e.g., charged residues such as Arg, Asp, His, Lys, and Glu) and replaced by a neutral or negatively charged amino acid (most preferably alanine or polyalanine).
  • Replacement of an amino acid can affect the interaction of the amino acids with the surrounding aqueous environment in or outside the cell.
  • Those domains demonstrating functional sensitivity to the substitutions can then be refined by introducing further or other variants at or for the sites of substitution.
  • the site for introducing an amino acid sequence variation is predetermined, the nature of the mutation per se need not be predetermined.
  • alanine scanning or random mutagenesis may be conducted at the target codon or region and the expressed desired protein subunit variants are screened for the optimal combination of desired activity.
  • Oligonucleotide-mediated mutagenesis is a useful method for preparing substitution, deletion, and insertion variants of DNA, see, e.g., Adelman et al., (DNA 2:183, 1983) incorporated herein by reference.
  • the desired DNA can be altered by hybridizing an oligonucleotide encoding a mutation to a DNA template, where the template is the single-stranded form of a plasmid or bacteriophage containing the unaltered or native DNA sequence of the desired protein.
  • a DNA polymerase is used to synthesize an entire second complementary strand of the template that will thus incorporate the oligonucleotide primer, and will code for the selected alteration in the desired protein DNA.
  • oligonucleotides of at least 25 nucleotides in length are used.
  • An optimal oligonucleotide will have 12 to 15 nucleotides that are completely complementary to the template on either side of the nucleotide(s) coding for the mutation. This ensures that the oligonucleotide will hybridize properly to the single-stranded DNA template molecule.
  • the oligonucleotides are readily synthesized using techniques known in the art such as that described by Crea et al. (Proc. Natl. Acad. Sci. USA, 75: 5765 [1978]) incorporated herein by reference. -Cassette Mutagenesis
  • the starting material can be a plasmid (or other vector) which includes the protein subunit DNA to be mutated.
  • the codon(s) in the protein subunit DNA to be mutated are identified.
  • the plasmid is cut at these sites to linearize it.
  • a double-stranded oligonucleotide encoding the sequence of the DNA between the restriction sites but containing the desired mutation(s) is synthesized using standard procedures. The two strands are synthesized separately and then hybridized together using standard techniques.
  • This double-stranded oligonucleotide is referred to as the cassette.
  • This cassette is designed to have 3' and 5' ends that are comparable with the ends of the linearized plasmid, such that it can be directly ligated to the plasmid.
  • This plasmid now contains the mutated desired protein subunit DNA sequence.
  • Combinatorial mutagenesis can also be used to generate mutants.
  • the amino acid sequences for a group of homologs or other related proteins are aligned, preferably to promote the highest homology possible. All of the amino acids which appear at a given position of the aligned sequences can be selected to create a degenerate set of combinatorial sequences.
  • the variegated library of variants is generated by combinatorial mutagenesis at the nucleic acid level, and is encoded by a variegated gene library.
  • a mixture of synthetic oligonucleotides can be enzymatically ligated into gene sequences such that the degenerate set of potential sequences are expressible as individual peptides, or alternatively, as a set of larger fusion proteins containing the set of degenerate sequences.
  • Various techniques are known in the art for screening generated mutant gene products. Techniques for screening large gene libraries often include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the genes under conditions in which detection of a desired activity, e.g., in this case, binding to Kay-ligand or its receptor, facilitates relatively easy isolation of the vector encoding the gene whose product was detected.
  • the invention also provides for reduction of the protein binding domains of the claimed polypeptides or their receptors, to generate mimetics, e.g. peptide or non- peptide agents.
  • mimetics e.g. peptide or non- peptide agents.
  • the peptide mimetics are able to disrupt binding of Kay-ligand with its receptor.
  • the critical residues of the Kay-ligand involved in molecular recognition of a receptor polypeptide or of a downstream intracellular protein can be determined and used to generate the Kay-ligand or its receptor-derived peptidomimetics which competitively or noncompetitively inhibit binding of the Kay-ligand with a receptor, (see, for example, "Peptide inhibitors of human papilloma virus protein binding to retinoblastoma gene protein" European patent applications EP-412,762A and EP- B31,080A), specifically incorporated herein by reference.
  • the present invention provides assays which can be used to screen for drug candidates which are either agonists or antagonists of the normal cellular function, in this case, of Kay- ligand, or its receptor.
  • the assay evaluates the ability of a compound to modulate binding between the Kay-ligand and their receptors.
  • assay formats will suffice and, in light of the present inventions, will be comprehended by the skilled artisan.
  • the effects of cellular toxicity and/or bioavailability of the test compound can be generally ignored in the in vitro system, the assay instead being focused primarily on the effect of the drug on the molecular target as may be manifest in an alteration of binding affinity with other proteins or change in enzymatic properties of the molecular target.
  • compositions of the invention may comprise a therapeutically effective amount of Kay-ligand, or its receptor, or fragments or mimetics thereof, and, optionally may include pharmaceutically acceptable carriers. Accordingly, this invention provides methods for treatment of cancer, and methods of stimulating, or in certain instances, inhibiting the immune system, or parts thereof by administering a pharmaceutically effective amount of a compound of the invention or its pharmaceutically acceptable salts or derivatives. It should of course by understood that the compositions and methods of this invention can be used in combination with other therapies for various treatments.
  • the compositions can be formulated for a variety of routes of administration, including systemic, topical or localized administration.
  • compositions of the invention can be formulated in liquid solutions, preferably in physiologically compatible buffers such as Hank's solution or Ringer's solution.
  • physiologically compatible buffers such as Hank's solution or Ringer's solution.
  • the compositions may be formulated in solid form and, optionally, redissolved or suspended immediately prior to use. Lyophilized forms are also included in the invention.
  • compositions can be administered orally, or by transmucosal or transdermal means.
  • penetrants appropriate to the barrier to be permeated are used in the formulation.
  • penetrants include, for example, for transmucosal administration, bile salts, fusidic acid derivatives, and detergents.
  • Transmucosal administration may be through nasal sprays or using suppositories.
  • the compositions are formulated into conventional oral administration forms such as capsules, tablets, and tonics.
  • topical administration the compositions of the invention are formulated into ointments, salves, gels, or creams as known in the art.
  • compositions of the invention will be in the form of a unit dose and will be administered one or more times a day.
  • the amount of active compound administered at one time or over the course of treatment will depend on many factors.
  • an effective dose may be in the range of from about 0.005 to about 5 mg kg/day, preferably about 0.05 to about 0.5 mg/kg/day.
  • an effective dose may be in the range of from about 0.005 to about 5 mg kg/day, preferably about 0.05 to about 0.5 mg/kg/day.
  • lower and higher doses may also be useful.
  • Gene constructs according to the invention can also be used as a part of a gene therapy protocol to deliver nucleic acids encoding either an agonistic or antagonistic form of a Kay-ligand polypeptide.
  • Expression constructs of the claimed Kay-ligand can be administered in any biologically effective carrier, e.g., any formulation or composition capable of effectively delivering the gene for the claimed Kay-ligand to cells in vivo.
  • Approaches include insertion of the gene in viral vectors which can transfect cells directly, or delivering plasmid DNA with the help of, for example, liposomes, or intracellular carriers, as well as direct injection of the gene construct. Viral vector transfer methods are preferred.
  • a pharmaceutical preparation of the gene therapy construct can consist essentially of the gene delivery system in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded.
  • the pharmaceutical preparation can comprise one or more cells which produce the gene delivery system.
  • the oligomers of the invention may be used as diagnostic reagents to detect the presence or absence of the target DNA, RNA or amino acid sequences to which they specifically bind.
  • the claimed invention may be used to evaluate a chemical entity for its ability to interact with, e.g., bind or physically associate with the claimed Kay-ligand, or fragment thereof.
  • the method includes contacting the chemical entity with the Kay-ligand, and evaluating the ability of the entity to interact with the Kay-ligand.
  • the Kay-ligand of the invention can be used in methods of evaluating naturally occurring Kay-ligand or receptors of the Kay-ligand, as well as to evaluate chemical entities which associate or bind with receptors of the Kay-ligand.
  • the claimed invention features a method for evaluating a chemical entity for the ability to modulate the interaction between Kay-ligand and its receptor.
  • the method includes combining a Kay-ligand receptor, and the Kay-ligand under conditions wherein the pair is capable of interacting, adding the chemical entity to be evaluated and detecting the formation or dissolution of complexes.
  • modulating agents may be further evaluated in vitro, e.g. by testing its activity in a cell free system, and then, optionally administering the compound to a cell or animal, and evaluating the effect.
  • Ligands of the TNF family can be used to identify and clone receptors.
  • the described Kay-ligand sequences one could fuse the 5' end of the extracellular domain of the Kay-ligand which constitutes the receptor binding sequence to a marker or tagging sequence and then add a leader sequence that will force secretion of the Kay- ligand in any of a number of expression systems.
  • a leader sequence that will force secretion of the Kay- ligand in any of a number of expression systems.
  • This technology is described by Browning et al., (1996) (IBC 271, 8618-8626) where the LT- ⁇ ligand was secreted in such a form.
  • the VCAM leader sequence was coupled to a short myc peptide tag followed by the extracellular domain of the LT- ⁇ .
  • the VCAM sequence is used to force secretion of the normally membrane bound LT- ⁇ molecule.
  • the secreted protein retains a myc tag on the N-terminus which does not impair the ability to bind to a receptor.
  • Such a secreted protein can be expressed in either transiently transfected Cos cells or a similar system, e.g., EBNA derived vectors, insect cell/baculovirus, picchia etc.
  • the unpurified cell supernatant can be used as a source of the tagged ligand.
  • Cells expressing the receptor can be identified by exposing them to the tagged ligand.
  • Cells with bound ligand are identified in a FACS experiment by labeling the myc tag with an anti-myc peptide antibody (9E10) followed by phycoerythrin (or a similar label) labeled anti-mouse immunoglobulin.
  • FACS positive cells can be readily identified and would serve as a source of RNA encoding for the receptor.
  • An expression library would then be prepared from this RNA via standard techniques and separated into pools. Pools of clones would be transfected into a suitable host cell and binding of the tagged ligand to receptor positive transfected cells determined via microscopic examination, following labeling of bound myc peptide tag with an enzyme labeled anti-mouse Ig reagent, i.e.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Cette invention se rapporte à Kay, nouveau membre de la famille des facteurs de nécrose des tumeurs (TNF), à des ligands Kay modifiés et à des compositions pharmaceutiques qui les renferment.
PCT/US1998/019037 1997-09-12 1998-09-11 Kay, nouvelle proteine du systeme immunitaire WO1999012964A2 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
CA002303424A CA2303424A1 (fr) 1997-09-12 1998-09-11 Kay, nouvelle proteine du systeme immunitaire
HU0004034A HUP0004034A3 (en) 1997-09-12 1998-09-11 Kay - a novel immune system protein
SK353-2000A SK3532000A3 (en) 1997-09-12 1998-09-11 Dna sequence coding for kay ligand, method for the preparation of kay ligand, pharmaceutical composition containing said ligand and the use thereof
IL13448098A IL134480A0 (en) 1997-09-12 1998-09-11 Kay - an immune system protein and dna sequences encoding the same
AU93152/98A AU9315298A (en) 1997-09-12 1998-09-11 Kay - a novel immune system protein
JP2000510769A JP2001515711A (ja) 1997-09-12 1998-09-11 Ｋａｙ−新規の免疫系タンパク質
EA200000311A EA200000311A1 (ru) 1997-09-12 1998-09-11 Новый белок иммунной системы - кау
EP98946052A EP1012270A2 (fr) 1997-09-12 1998-09-11 Kay, nouvelle proteine du systeme immunitaire
BR9812433-1A BR9812433A (pt) 1997-09-12 1998-09-11 Kay- uma proteìna do sistema de imunização
EEP200000148A EE200000148A (et) 1997-09-12 1998-09-11 Kay - uus immuunsüsteemi valk
KR1020007002576A KR20010023892A (ko) 1997-09-12 1998-09-11 Ｋａｙ-신규 면역계 단백질
IS5375A IS5375A (is) 1997-09-12 2000-02-11 KAY-nýstárlegt ónæmisprótín
NO20001240A NO20001240L (no) 1997-09-12 2000-03-09 Kay-A immunsystemprotein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5878697P 1997-09-12 1997-09-12
US60/058,786 1997-09-12

Publications (2)

Publication Number Publication Date
WO1999012964A2 true WO1999012964A2 (fr) 1999-03-18
WO1999012964A3 WO1999012964A3 (fr) 1999-05-27

Family

ID=22018915

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/019037 WO1999012964A2 (fr) 1997-09-12 1998-09-11 Kay, nouvelle proteine du systeme immunitaire

Country Status (17)

Country Link
EP (1) EP1012270A2 (fr)
JP (1) JP2001515711A (fr)
KR (1) KR20010023892A (fr)
CN (1) CN1269832A (fr)
AU (1) AU9315298A (fr)
BR (1) BR9812433A (fr)
CA (1) CA2303424A1 (fr)
EA (1) EA200000311A1 (fr)
EE (1) EE200000148A (fr)
HU (1) HUP0004034A3 (fr)
IL (1) IL134480A0 (fr)
IS (1) IS5375A (fr)
NO (1) NO20001240L (fr)
PL (1) PL339740A1 (fr)
SK (1) SK3532000A3 (fr)
TR (1) TR200000654T2 (fr)
WO (1) WO1999012964A2 (fr)

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0921194A2 (fr) * 1997-11-26 1999-06-09 Eli Lilly And Company TRAILLK-2: membre de la famille des ligand du TNF
WO1999033980A2 (fr) * 1997-12-30 1999-07-08 Chiron Corporation Membres de familles de tnf et de tnfr
WO2000060079A2 (fr) * 1999-04-05 2000-10-12 Chiron Corporation Nouveaux membres des familles tnf et tnfr
WO2000068378A1 (fr) * 1999-05-06 2000-11-16 National Jewish Medical And Research Center Molecules d'acide nucleique, proteines et recepteurs tall-1, et procedes d'utilisation
WO2001012812A2 (fr) * 1999-08-17 2001-02-22 Biogen, Inc. Recepteur de baff (bcma) et agent immunoregulateur
EP1146894A1 (fr) * 1999-02-02 2001-10-24 Research Development Foundation Utilisation de thank, un homologue du tnf activant l'apoptose
US6403770B1 (en) 1996-10-25 2002-06-11 Human Genome Sciences, Inc. Antibodies to neutrokine-alpha
JP2003510366A (ja) * 1999-10-06 2003-03-18 バイオジェン インコーポレイテッド Ａｐｒｉｌレセプター（ｂｃｍａ）およびその使用
EP1309718A2 (fr) * 2000-08-15 2003-05-14 Human Genome Sciences, Inc. Neutrokine-alpha et variant d'epissage de neutrokine-alpha
EP1415659A1 (fr) 1999-01-25 2004-05-06 Biogen Inc. BAFF et ses inhibiteurs, leur utilisation pour moduler la réponse des cellules B
US6774106B2 (en) 2000-05-12 2004-08-10 Amgen Inc. Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3 and TACI
US6875846B2 (en) 2000-02-11 2005-04-05 Biogen Idec Ma Inc. Heterologous polypeptide of the TNF family
WO2006041680A2 (fr) 2004-10-05 2006-04-20 Genentech, Inc. Methode de traitement de l'angeite
EP1666052A1 (fr) 2000-02-16 2006-06-07 Genentech, Inc. Utilisation d'agonistes ou d'antagonistes pour moduler l'activite de molecules associees au tnf
WO2006067210A1 (fr) 2004-12-23 2006-06-29 Laboratoires Serono S.A. Polypeptides bcma et leurs utilisations
US7112421B2 (en) 2000-09-18 2006-09-26 Biogen Idec Ma Inc. Nucleic acids encoding BAFF receptor, chimeric proteins and methods and compositions related thereto
US7138501B2 (en) 2000-06-16 2006-11-21 Human Genome Sciences, Inc. Antibodies that immunospecifically bind BLyS
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
US7259137B2 (en) 2001-05-11 2007-08-21 Amgen Inc. Peptides and related molecules that bind to TALL-1
EP1860190A2 (fr) * 1999-02-23 2007-11-28 Human Genome Sciences, Inc. Variantes d'épissage de neutrokine-alpha, et neutrokine-alpha
US7317089B2 (en) 2001-08-16 2008-01-08 Eli Lilly And Company Antagonistic anti-hTNFSF13b human antibodies
US7399593B1 (en) 1998-12-23 2008-07-15 Smithkline Beecham Corporation Member of the TNF ligand family
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US7700317B2 (en) 2003-03-28 2010-04-20 Biogen Idec Ma Inc. Truncated baff receptors
WO2010075249A2 (fr) 2008-12-22 2010-07-01 Genentech, Inc. Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b
US7772365B2 (en) 1999-01-07 2010-08-10 Zymogenetics, Inc. Soluble receptor BR43x2
US7842292B2 (en) 2005-08-09 2010-11-30 Ares Trading S.A. Methods for treating B-cell malignancies using a TACI-Ig fusion molecule
EP2272868A2 (fr) 2003-06-05 2011-01-12 Genentech, Inc. Thérapie de combinaison pour des désordres de cellules B
EP2332563A2 (fr) 2004-10-13 2011-06-15 The Washington University Utilisation de BAFF pour traiter la sepsie
US8062906B2 (en) 2000-08-18 2011-11-22 Human Genome Sciences, Inc. B-lymphocyte stimulator binding polypeptides and methods based thereon
US8105603B2 (en) * 2004-01-29 2012-01-31 Genentech, Inc. Polypeptides that bind APRIL
US8133976B2 (en) 1999-04-30 2012-03-13 Immunex Corporation Methods of use of the TACI/TACI-L interaction
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
WO2012118750A2 (fr) 2011-02-28 2012-09-07 Genentech, Inc. Marqueurs biologiques et procédés de prédiction de réponse à des antagonistes de lymphocytes b
US8728730B2 (en) 2009-09-03 2014-05-20 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
US8784812B2 (en) 2006-05-15 2014-07-22 Zymogenetics, Inc. Methods for treating autoimmune diseases using a TACI-Ig fusion molecule
US8808696B2 (en) 2005-08-09 2014-08-19 Ares Trading S.A. Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
US9387237B2 (en) 2003-10-20 2016-07-12 Biogen Ma Inc. Methods of treating a patient having an autoimmune disorder by administering a soluble BCMA
US9545086B2 (en) 1999-01-25 2017-01-17 Biogen Ma Inc. BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US9726673B2 (en) 2005-11-23 2017-08-08 Genentech, Inc. Methods and compositions related to B cell assays
US9963513B2 (en) 2013-02-05 2018-05-08 Engmab Sàrl Method for the selection of antibodies against BCMA
US10138251B2 (en) 2014-04-11 2018-11-27 Boehringer Ingelheim International Gmbh Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors
US10421823B2 (en) 2013-03-13 2019-09-24 Amgen Inc. Proteins specific for BAFF and B7RP1 and uses thereof
US10421824B2 (en) 2013-03-13 2019-09-24 Amgen Inc. Proteins specific for BAFF and B7RP1
US10450379B2 (en) 2005-11-15 2019-10-22 Genetech, Inc. Method for treating joint damage

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018325A1 (fr) * 1993-02-03 1994-08-18 N.V. Innogenetics S.A. Muteines de tnf-alpha et leur procede de preparation
WO1996040774A1 (fr) * 1995-06-07 1996-12-19 Biogen, Inc. Complexes de lymphotoxines modifiees utilises comme preparations pharmaceutiques
WO1998018921A1 (fr) * 1996-10-25 1998-05-07 Human Genome Sciences, Inc. Neutrokine alpha
WO1998027114A2 (fr) * 1996-12-17 1998-06-25 Schering Corporation Antigenes de surface mammaliens et reactifs associes
EP0869180A1 (fr) * 1997-04-02 1998-10-07 Smithkline Beecham Corporation Un homologue de TNF, TL5

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018325A1 (fr) * 1993-02-03 1994-08-18 N.V. Innogenetics S.A. Muteines de tnf-alpha et leur procede de preparation
WO1996040774A1 (fr) * 1995-06-07 1996-12-19 Biogen, Inc. Complexes de lymphotoxines modifiees utilises comme preparations pharmaceutiques
WO1998018921A1 (fr) * 1996-10-25 1998-05-07 Human Genome Sciences, Inc. Neutrokine alpha
WO1998027114A2 (fr) * 1996-12-17 1998-06-25 Schering Corporation Antigenes de surface mammaliens et reactifs associes
EP0869180A1 (fr) * 1997-04-02 1998-10-07 Smithkline Beecham Corporation Un homologue de TNF, TL5

Cited By (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403770B1 (en) 1996-10-25 2002-06-11 Human Genome Sciences, Inc. Antibodies to neutrokine-alpha
US6562579B1 (en) 1996-10-25 2003-05-13 Human Genome Sciences, Inc. Diagnostic methods using antibodies to Neutrokine-alpha
US8071092B1 (en) 1996-10-25 2011-12-06 Human Genome Sciences, Inc. Methods of inhibiting B lymphocytes using antibodies to Neutrokine-alpha
US8303951B2 (en) 1996-10-25 2012-11-06 Human Genome Sciences, Inc. Neutrokine-alpha antibodies and methods of use thereof
US6635482B1 (en) 1996-10-25 2003-10-21 Human Genome Sciences, Inc. Monoclonal antibodies to membrane neutrokine-α
US8231873B2 (en) 1996-10-25 2012-07-31 Human Genome Sciences, Inc. Methods of treatment using antibodies to Neutrokine-alpha
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US6881401B1 (en) 1996-10-25 2005-04-19 Human Genome Sciences, Inc. Methods of treatment of immune system related disorders using Neutrokine-alpha
US8173122B2 (en) 1996-10-25 2012-05-08 Human Genome Sciences, Inc. Methods of treatment using antibodies to neutrokine-alpha
EP0921194A3 (fr) * 1997-11-26 1999-07-07 Eli Lilly And Company TRAILLK-2: membre de la famille des ligand du TNF
EP0921194A2 (fr) * 1997-11-26 1999-06-09 Eli Lilly And Company TRAILLK-2: membre de la famille des ligand du TNF
WO1999033980A3 (fr) * 1997-12-30 1999-11-18 Chiron Corp Membres de familles de tnf et de tnfr
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
WO1999033980A2 (fr) * 1997-12-30 1999-07-08 Chiron Corporation Membres de familles de tnf et de tnfr
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US7399593B1 (en) 1998-12-23 2008-07-15 Smithkline Beecham Corporation Member of the TNF ligand family
US8216576B2 (en) 1998-12-23 2012-07-10 Glaxo Group Limited Method for inhibiting binding to B-cell receptor
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US7772365B2 (en) 1999-01-07 2010-08-10 Zymogenetics, Inc. Soluble receptor BR43x2
EP2974736A1 (fr) 1999-01-25 2016-01-20 Biogen MA Inc. Baff, ses inhibiteurs et leur utilisation pour moduler la réponse immunitaire des cellules b
CZ299819B6 (cs) * 1999-01-25 2008-12-03 Biogen Idec Ma Inc. Farmaceutické kompozice obsahující protilátky specifické pro rozpustný BAFF
US9545086B2 (en) 1999-01-25 2017-01-17 Biogen Ma Inc. BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
EP1415659A1 (fr) 1999-01-25 2004-05-06 Biogen Inc. BAFF et ses inhibiteurs, leur utilisation pour moduler la réponse des cellules B
US6869605B2 (en) 1999-01-25 2005-03-22 Biogen Idec Ma Inc. BAFF, inhibitors thereof and their use in the modulation of B-cell response
EP2298332A1 (fr) 1999-01-25 2011-03-23 Biogen Idec MA Inc. BAFF, ses inhibiteurs et leur utilisation pour moduler la réponse immunitaire des cellules B et des immunoglobulines
EP2319527A2 (fr) 1999-01-25 2011-05-11 Biogen Idec MA Inc. BAFF, ses inhibiteurs et leur utilisation pour moduler la réponse immunitaire des cellules B et des immunoglobulines
EP1146894A4 (fr) * 1999-02-02 2003-02-26 Res Dev Foundation Utilisation de thank, un homologue du tnf activant l'apoptose
US7241576B2 (en) 1999-02-02 2007-07-10 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
EP1146894A1 (fr) * 1999-02-02 2001-10-24 Research Development Foundation Utilisation de thank, un homologue du tnf activant l'apoptose
EP1860190A3 (fr) * 1999-02-23 2008-03-12 Human Genome Sciences, Inc. Variantes d'épissage de neutrokine-alpha, et neutrokine-alpha
EP1860190A2 (fr) * 1999-02-23 2007-11-28 Human Genome Sciences, Inc. Variantes d'épissage de neutrokine-alpha, et neutrokine-alpha
WO2000060079A3 (fr) * 1999-04-05 2001-06-28 Chiron Corp Nouveaux membres des familles tnf et tnfr
WO2000060079A2 (fr) * 1999-04-05 2000-10-12 Chiron Corporation Nouveaux membres des familles tnf et tnfr
US8133976B2 (en) 1999-04-30 2012-03-13 Immunex Corporation Methods of use of the TACI/TACI-L interaction
WO2000068378A1 (fr) * 1999-05-06 2000-11-16 National Jewish Medical And Research Center Molecules d'acide nucleique, proteines et recepteurs tall-1, et procedes d'utilisation
US6475987B1 (en) 1999-05-06 2002-11-05 National Jewish Medical And Research Center Tall-1 receptor homologues
JP4787439B2 (ja) * 1999-08-17 2011-10-05 バイオジェン・アイデック・エムエイ・インコーポレイテッド 免疫調節因子であるｂａｆｆレセプター（ｂｃｍａ）
JP2003507364A (ja) * 1999-08-17 2003-02-25 バイオジェン インコーポレイテッド 免疫調節因子であるｂａｆｆレセプター（ｂｃｍａ）
EP1806143A3 (fr) * 1999-08-17 2007-07-18 Biogen Idec MA, Inc. Récepteur Baff (BCMA), agent immunorégulateur
US7083785B2 (en) 1999-08-17 2006-08-01 Biogen Idcc MA Inc. Methods of treatment by administering an anti-BCMA antibody
WO2001012812A3 (fr) * 1999-08-17 2001-09-07 Biogen Inc Recepteur de baff (bcma) et agent immunoregulateur
US9650430B2 (en) 1999-08-17 2017-05-16 Biogen, Ma Inc. Methods of treating autoimmune diseases using a B-cell maturation antigen (BCMA)
CN100447244C (zh) * 1999-08-17 2008-12-31 比奥根艾迪克Ma公司 Baff受体(bcma),一种免疫调节剂
EP2314694A2 (fr) 1999-08-17 2011-04-27 Biogen Idec MA Inc. Récepteur BAFF (BCMA), agent immunorégulateur
WO2001012812A2 (fr) * 1999-08-17 2001-02-22 Biogen, Inc. Recepteur de baff (bcma) et agent immunoregulateur
US8828669B2 (en) 1999-08-17 2014-09-09 Biogen Idec Ma Inc. Methods of screening for a compound that inhibits the interaction between BAFF and BCMA
JP2014037434A (ja) * 1999-08-17 2014-02-27 Biogen Idec Ma Inc 免疫調節因子であるｂａｆｆレセプター（ｂｃｍａ）
US7691804B2 (en) 1999-08-17 2010-04-06 Biogen Idec Ma Inc. BAFF receptor (BCMA), an immunoregulatory agent
US10494416B2 (en) 1999-08-17 2019-12-03 Biogen Ma Inc. Methods of modulating immune responses using BCMA polypeptide
JP2011063600A (ja) * 1999-08-17 2011-03-31 Biogen Idec Ma Inc 免疫調節因子であるｂａｆｆレセプター（ｂｃｍａ）
JP2003510366A (ja) * 1999-10-06 2003-03-18 バイオジェン インコーポレイテッド Ａｐｒｉｌレセプター（ｂｃｍａ）およびその使用
EP2324844A2 (fr) 1999-10-06 2011-05-25 Biogen Idec MA Inc. Récepteur de APRIL (BCMA) et utilisations associées
US7276241B2 (en) 1999-10-06 2007-10-02 Biogen Idec Ma Inc. Methods of treating a tumor that expresses APRIL by administering BCMA
US6875846B2 (en) 2000-02-11 2005-04-05 Biogen Idec Ma Inc. Heterologous polypeptide of the TNF family
EP1666052A1 (fr) 2000-02-16 2006-06-07 Genentech, Inc. Utilisation d'agonistes ou d'antagonistes pour moduler l'activite de molecules associees au tnf
US6774106B2 (en) 2000-05-12 2004-08-10 Amgen Inc. Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3 and TACI
US8101181B2 (en) 2000-06-16 2012-01-24 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
US7138501B2 (en) 2000-06-16 2006-11-21 Human Genome Sciences, Inc. Antibodies that immunospecifically bind BLyS
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
US7605236B2 (en) 2000-06-16 2009-10-20 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
US9187548B2 (en) 2000-06-16 2015-11-17 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
EP1309718A4 (fr) * 2000-08-15 2004-08-25 Human Genome Sciences Inc Neutrokine-alpha et variant d'epissage de neutrokine-alpha
EP1309718A2 (fr) * 2000-08-15 2003-05-14 Human Genome Sciences, Inc. Neutrokine-alpha et variant d'epissage de neutrokine-alpha
US8062906B2 (en) 2000-08-18 2011-11-22 Human Genome Sciences, Inc. B-lymphocyte stimulator binding polypeptides and methods based thereon
US8524672B2 (en) 2000-09-18 2013-09-03 Biogen Idec Ma Inc. Method for inhibiting BAFF-R activity
US8026072B2 (en) 2000-09-18 2011-09-27 Biogen Idec Ma Inc. Method of identifying compounds that bind BAFF-R
US7112421B2 (en) 2000-09-18 2006-09-26 Biogen Idec Ma Inc. Nucleic acids encoding BAFF receptor, chimeric proteins and methods and compositions related thereto
US7635677B2 (en) 2000-09-18 2009-12-22 Biogen Idec Ma Inc. BAFF receptor polypeptides
US7638327B2 (en) 2000-09-18 2009-12-29 Biogen Idec Ma Inc. BAFF receptor antibodies and methods
US7709220B2 (en) 2000-09-18 2010-05-04 Biogen Idec Ma Inc. Methods of monitoring treatment of BAFF-R related disease
US7259137B2 (en) 2001-05-11 2007-08-21 Amgen Inc. Peptides and related molecules that bind to TALL-1
EP2292655A1 (fr) 2001-05-11 2011-03-09 Amgen SF, LLC Peptides et molécules associées qui sont liées à tall-1
US9139645B2 (en) 2001-05-11 2015-09-22 Amgen Inc. Peptides and related molecules that bind to TALL-1
EP2845864A2 (fr) 2001-05-11 2015-03-11 Amgen, Inc Peptides et les molécules qui se lient à TALL - 1
US8507426B2 (en) 2001-05-11 2013-08-13 Amgen, Inc. Peptides and related molecules that bind to TALL-1
US7737111B2 (en) 2001-05-11 2010-06-15 Amgen, Inc. Peptides and related molecules that bind to TALL-1
US7728109B2 (en) 2001-08-16 2010-06-01 Eli Lilly And Company Antagonistic anti-hTNFSF13b human antibodies
US8173124B2 (en) 2001-08-16 2012-05-08 Eli Lilly And Company Method to treat using antagonistic anti-hTNFSF13b human antibodies
US7317089B2 (en) 2001-08-16 2008-01-08 Eli Lilly And Company Antagonistic anti-hTNFSF13b human antibodies
US8303958B2 (en) 2003-03-28 2012-11-06 Biogen Idec Ma Inc. Method of treating immunological disorders by administering truncated BAFF receptors
US7700317B2 (en) 2003-03-28 2010-04-20 Biogen Idec Ma Inc. Truncated baff receptors
US8022182B2 (en) 2003-03-28 2011-09-20 Biogen Idec Ma Inc. Truncated BAFF receptors
US8821883B2 (en) 2003-03-28 2014-09-02 Biogen Idec Ma Inc. Method of treating B cell cancers by administering truncated BAFF receptors
EP2272868A2 (fr) 2003-06-05 2011-01-12 Genentech, Inc. Thérapie de combinaison pour des désordres de cellules B
US9387237B2 (en) 2003-10-20 2016-07-12 Biogen Ma Inc. Methods of treating a patient having an autoimmune disorder by administering a soluble BCMA
US8105603B2 (en) * 2004-01-29 2012-01-31 Genentech, Inc. Polypeptides that bind APRIL
WO2006041680A2 (fr) 2004-10-05 2006-04-20 Genentech, Inc. Methode de traitement de l'angeite
EP2332563A2 (fr) 2004-10-13 2011-06-15 The Washington University Utilisation de BAFF pour traiter la sepsie
WO2006067210A1 (fr) 2004-12-23 2006-06-29 Laboratoires Serono S.A. Polypeptides bcma et leurs utilisations
US8808696B2 (en) 2005-08-09 2014-08-19 Ares Trading S.A. Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
US7842292B2 (en) 2005-08-09 2010-11-30 Ares Trading S.A. Methods for treating B-cell malignancies using a TACI-Ig fusion molecule
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
US10450379B2 (en) 2005-11-15 2019-10-22 Genetech, Inc. Method for treating joint damage
US10654940B2 (en) 2005-11-15 2020-05-19 Genentech, Inc. Method for treating joint damage
US9726673B2 (en) 2005-11-23 2017-08-08 Genentech, Inc. Methods and compositions related to B cell assays
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
US8784812B2 (en) 2006-05-15 2014-07-22 Zymogenetics, Inc. Methods for treating autoimmune diseases using a TACI-Ig fusion molecule
WO2010075249A2 (fr) 2008-12-22 2010-07-01 Genentech, Inc. Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b
US9822400B2 (en) 2009-09-03 2017-11-21 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
EP3211094A2 (fr) 2009-09-03 2017-08-30 F. Hoffmann-La Roche AG Procédés pour traiter, diagnostiquer, et surveiller la polyarthrite rhumatoïde
US8728730B2 (en) 2009-09-03 2014-05-20 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
US9982302B2 (en) 2011-02-28 2018-05-29 Genentech, Inc. Biological markers and methods for predicting response to B-cell antagonists
WO2012118750A2 (fr) 2011-02-28 2012-09-07 Genentech, Inc. Marqueurs biologiques et procédés de prédiction de réponse à des antagonistes de lymphocytes b
US9963513B2 (en) 2013-02-05 2018-05-08 Engmab Sàrl Method for the selection of antibodies against BCMA
US10077315B2 (en) 2013-02-05 2018-09-18 Engmab Sàrl Bispecific antibodies against CD3 and BCMA
US10851171B2 (en) 2013-02-05 2020-12-01 Engmab Sarl Method for the selection of antibodies against BCMA
US10421823B2 (en) 2013-03-13 2019-09-24 Amgen Inc. Proteins specific for BAFF and B7RP1 and uses thereof
US10421824B2 (en) 2013-03-13 2019-09-24 Amgen Inc. Proteins specific for BAFF and B7RP1
US11492417B2 (en) 2013-03-13 2022-11-08 Amgen Inc. Proteins specific for BAFF and B7RP1 and uses thereof
US10138251B2 (en) 2014-04-11 2018-11-27 Boehringer Ingelheim International Gmbh Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors

Also Published As

Publication number Publication date
EA200000311A1 (ru) 2000-10-30
WO1999012964A3 (fr) 1999-05-27
HUP0004034A3 (en) 2002-08-28
JP2001515711A (ja) 2001-09-25
CA2303424A1 (fr) 1999-03-18
EE200000148A (et) 2001-02-15
CN1269832A (zh) 2000-10-11
SK3532000A3 (en) 2001-12-03
NO20001240D0 (no) 2000-03-09
KR20010023892A (ko) 2001-03-26
IS5375A (is) 2000-02-11
IL134480A0 (en) 2001-04-30
AU9315298A (en) 1999-03-29
NO20001240L (no) 2000-05-10
HUP0004034A2 (en) 2001-03-28
TR200000654T2 (tr) 2000-07-21
EP1012270A2 (fr) 2000-06-28
BR9812433A (pt) 2000-09-26
PL339740A1 (en) 2001-01-02

Similar Documents

Publication Publication Date Title
EP1012270A2 (fr) Kay, nouvelle proteine du systeme immunitaire
US7695934B2 (en) Tumor necrosis factor related ligand
JP4411330B2 (ja) 腫瘍壊死因子関連リガンド
AU759717B2 (en) April- a novel protein with growth effects
AU774498B2 (en) A tumor necrosis factor related ligand
CZ2000867A3 (cs) Sekvence DNA kódující ligand Kay, způsob přípravy ligandu Kay a farmaceutický přípravek obsahující tento ligand
MXPA99001342A (en) A tumor necrosis factor related ligand

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 134480

Country of ref document: IL

Ref document number: 98809023.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 93152/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PV2000-867

Country of ref document: CZ

Ref document number: 2000/00654

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: PA/A/2000/002410

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2303424

Country of ref document: CA

Ref document number: 2303424

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020007002576

Country of ref document: KR

Ref document number: 3532000

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 2000 510769

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1998946052

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 503849

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 200000311

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1998946052

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2000-867

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020007002576

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV2000-867

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1998946052

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020007002576

Country of ref document: KR